Company / SG&A Expense
Seres Therapeutics, Inc. SG&A Expense History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$77.5M
FY2025
5-year range
$24.7M / $77.5M
FY2021-FY2025
Trend
+11.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 3 consecutive years, from $25M in FY2021 to $78M in FY2025.
Based on SEC 10-K filings.
$78M in FY2025 with a 10-year CAGR of +51.1%.
Increased from $31M to $78M over the past 3 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +36.1%
- 5-Year CAGR
- +18.9%
- 10-Year CAGR
- +51.1%
Key checks
Key Insights
- Seres Therapeutics, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +18.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 11.9% year-over-year.
- Lowest sg&a expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $77.5M | +11.9% |
| FY2023 | $69.3M | +125.1% |
| FY2022 | $30.8M | +24.4% |
| FY2021 | $24.7M | -24.1% |
| FY2020 | $32.6M | -4.2% |
| FY2019 | $34.0M | +4.4% |
| FY2018 | $32.6M | +94.6% |
| FY2017 | $16.8M | +284.1% |
| FY2016 | $4.4M | +250.0% |
| FY2015 | $1.2M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026